SPRO Stock Gets Stronger EPS Estimate from HC Wainwright

Spero Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its Q4 2026 EPS estimate for Spero Therapeutics to a loss of $0.12 per share from a loss of $0.14, maintaining a Buy rating and $6 price target.
  • Spero reported a quarterly loss of $0.76 per share, missing the consensus estimate of a $0.47 loss by $0.29.
  • Analyst sentiment is mixed: MarketBeat’s consensus rating is Hold, with an average $6 price target; shares opened at $0.90, near the stock’s 12-month low of $0.88.
  • Interested in Spero Therapeutics? Here are five stocks we like better.

Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - HC Wainwright boosted their Q4 2026 earnings per share (EPS) estimates for Spero Therapeutics in a research report issued to clients and investors on Monday, November 16th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.12) for the quarter, up from their previous forecast of ($0.14). HC Wainwright has a "Buy" rating and a $6.00 price target on the stock. The consensus estimate for Spero Therapeutics' current full-year earnings is ($0.97) per share.

SPRO has been the subject of several other reports. Wall Street Zen cut shares of Spero Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday. Weiss Ratings upgraded shares of Spero Therapeutics from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Tuesday, November 10th. Cantor Fitzgerald started coverage on shares of Spero Therapeutics in a research report on Wednesday, October 28th. They set an "overweight" rating and a $6.00 price target on the stock. Compass Point raised shares of Spero Therapeutics to a "neutral" rating in a report on Monday, September 14th. Finally, Zacks Research upgraded shares of Spero Therapeutics to a "hold" rating in a research report on Monday, September 14th. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $6.00.

Check Out Our Latest Stock Analysis on Spero Therapeutics

Spero Therapeutics Price Performance

Shares of NASDAQ SPRO opened at $0.90 on Wednesday. The stock has a market capitalization of $52.51 million, a price-to-earnings ratio of 11.83 and a beta of 1.59. The firm's 50 day simple moving average is $1.13 and its 200-day simple moving average is $1.90. Spero Therapeutics has a 12 month low of $0.88 and a 12 month high of $3.08.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.29). Spero Therapeutics had a net margin of 24.90% and a return on equity of 13.98%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Susquehanna Fundamental Investments LLC purchased a new stake in Spero Therapeutics in the 2nd quarter worth $36,000. Global Retirement Partners LLC acquired a new position in Spero Therapeutics during the second quarter worth $55,000. Empowered Funds LLC purchased a new position in Spero Therapeutics during the third quarter valued at $77,000. Marshall Wace LLP purchased a new position in Spero Therapeutics during the third quarter valued at $236,000. Finally, GSA Capital Partners LLP purchased a new position in Spero Therapeutics during the second quarter valued at $632,000. Hedge funds and other institutional investors own 25.60% of the company's stock.

Insider Buying and Selling

In other news, insider Esther Rajavelu sold 40,851 shares of the business's stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $1.04, for a total value of $42,485.04. Following the completion of the sale, the insider directly owned 946,000 shares in the company, valued at $983,840. The trade was a 4.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.90% of the company's stock.

Spero Therapeutics Company Profile

(Get Free Report)

Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious and difficult-to-treat bacterial infections. Its work has centered on antibiotic candidates intended to address infections for which existing treatment options may be limited. The company's pipeline has included tebipenem HBr, an oral antibiotic candidate studied for complicated urinary tract infections, and programs targeting drug-resistant Gram-negative bacteria and nontuberculous mycobacterial infections.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Spero Therapeutics Right Now?

Before you consider Spero Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spero Therapeutics wasn't on the list.

While Spero Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines